Navigation

Lung cancer (non-small cell) - afatinib [ID357]

Afatinib for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib

Status: Suspended
Expected date of issue: TBC
Referral date: July 2010
Process: STA
Notes:

Scoped within Batch 12

Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update

28 July 2011

 

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of afatinib within its licensed indication for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib as part of our 22nd wave work programme. 

The Institute has been informed by the manufacturer that it is not expecting to receive a separate marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

This indication is now planned to be part of the regulatory submission of afatinib for NSCLC, locally advanced and/or metastatic with EGFR mutation positive.

3 December 2010

 

Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established.

 

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.